Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation

被引：23
|
作者：
Cutting, Rob [1 ]
Mirelman, Anna [1 ]
Vora, Ajay [1 ]
机构：
[1] Sheffield Childrens Hosp, Dept Paediat Haematol, Sheffield S10 2TH, S Yorkshire, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 143卷 / 05期
关键词：
child; allogeneic transplant; treosulphan; conditioning;
D O I：
10.1111/j.1365-2141.2008.07399.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：748 / 751
页数：4
相关论文
共 50 条
  • [21] Myeloablative conditioning before allogeneic transplantation for adult acute leukaemia in first and second remission with daily intravenous busulphan, fludarabine, 400 cGy total body irradiation and thymoglobulin
    Russell, J.
    Savoie, L.
    Balogh, A.
    Bahlis, N.
    Chaudhry, A.
    Quinlan, D.
    Geddes, M.
    Brown, C.
    Storek, J.
    Larratt, L.
    Turner, R.
    Stewart, D.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S6 - S6
  • [22] Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia
    Mengarelli, A
    Iori, A
    Guglielmi, C
    Romano, A
    Cerretti, R
    Torromeo, C
    Micozzi, A
    Fenu, S
    Laurenti, L
    Donato, V
    De Felice, L
    Arcese, W
    HAEMATOLOGICA, 2002, 87 (01) : 52 - 58
  • [23] Comparison of adult allogeneic umbilical cord blood transplantation between myeloablative and non-myeloablative conditioning regimens
    Tashiro, H
    Kozai, Y
    Goto, M
    Noguchi, M
    Shirasaki, R
    Kawasugi, K
    Kodo, H
    Shirafuji, N
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (11) : 929 - 929
  • [24] Allogeneic HSCT with reduced intensity versus myeloablative conditioning regimens in paediatric acute lymphoblastic leukaemia
    Semenova, E.
    Stancheva, N.
    Kazantsev, I.
    Vasilieva, Y.
    Kostorov, V.
    Shiryaev, S.
    Afanasyev, B.
    Zubarovskaya, L.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S285 - S285
  • [25] Myeloablative conditioning with intravenous busulphan in a single daily dose and fludarabine for HLA-identical sibling allogeneic HSCT in myeloid malignancies
    de la Serna, J.
    Bermudez, A.
    Sanz, J.
    Caballero, D.
    Serrano, D.
    de la Camara, R.
    Vallejo, C.
    Moraleda, J.
    Noblejas, A. Garcia
    Cabrero, M.
    Lahuerta, J. J.
    Iriondo, A.
    Benlloch, L.
    Sanz, G.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S294 - S295
  • [26] Incidence and outcome of thrombotic microangiopathy after allogeneic peripheral blood stem cell transplantation with non-myeloablative conditioning compared with myeloablative conditioning
    Willems, E
    Baron, F
    Fillet, G
    Beguin, Y
    BONE MARROW TRANSPLANTATION, 2006, 37 : S46 - S46
  • [27] Lymphocyte Recovery Kinetics in Patients Undergoing Myeloablative Conditioning and Allogeneic Stem Cell Transplantation
    Kobulnicky, David Jared
    Sabo, Roy T.
    Ali, Ali S. Shubar
    Roberts, Catherine H.
    Scalora, Allison F.
    Kobulnicky, Kristen M.
    Song, Shiyu
    Clark, William B.
    Chung, Harold M.
    McCarty, John M.
    Neale, Michael C.
    Tour, Amir A.
    BLOOD, 2015, 126 (23)
  • [28] Myelo-ablative conditioning with busulphan, cyclophosphamide and cytarabine for AML and MDS followed by allogeneic transplantation.
    Alousi, AM
    Klein, JL
    Hamm, C
    Dansey, RD
    Abella, E
    Zonder, J
    Dudley, A
    Baynes, RD
    BLOOD, 2001, 98 (11) : 410A - 410A
  • [29] Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies
    Gürman, G
    Arat, M
    Ilhan, O
    Konuk, N
    Beksaç, M
    Çelebi, H
    Özcan, M
    Arslan, Ö
    Üstün, C
    Akan, H
    Uysal, A
    Koç, H
    CYTOTHERAPY, 2001, 3 (04) : 253 - 260
  • [30] Treosulfan/fludarabine - a low toxicity but myeloablative conditioning for allogeneic hematopoietic stem cell transplantation
    Holowiecki, J
    Giebel, S
    Wojnar, J
    Krawczyk-Kulis, M
    Wylezol, I
    Kruzel, T
    Markiewicz, M
    BLOOD, 2004, 104 (11) : 292A - 292A
12345